Nasal and Pulmonary Drug Delivery Systems

2018 ◽  
pp. 79-134
Author(s):  
Pranav Ponkshe ◽  
Ruchi Amit Thakkar ◽  
Tarul Mulay ◽  
Rohit Joshi ◽  
Ankit Javia ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Pulmonary Drug Delivery

Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems

2018 ◽  
Vol 5 (4) ◽  
Author(s):  
Kamal Dua ◽  
Mary Bebawy ◽  
Rajendra Awasthi ◽  
Rakesh K. Tekade ◽  
Muktika Tekade ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Pulmonary Drug Delivery

scholarly journals Polyhydroxyalkanoate Nanoparticles for Pulmonary Drug Delivery: Interaction with Lung Surfactant

Nanomaterials ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1482
Author(s):  
Olga Cañadas ◽  
Andrea García-García ◽  
M. Auxiliadora Prieto ◽  
Jesús Pérez-Gil
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Bacterial Species ◽  
High Surface ◽  
Lung Surfactant ◽  
Delivery Systems ◽  
Pulmonary Drug Delivery ◽  
Epifluorescence Microscopy ◽  
Energy Storage Materials ◽  
The Stability

Polyhydroxyalkanoates (PHA) are polyesters produced intracellularly by many bacterial species as energy storage materials, which are used in biomedical applications, including drug delivery systems, due to their biocompatibility and biodegradability. In this study, we evaluated the potential application of this nanomaterial as a basis of inhaled drug delivery systems. To that end, we assessed the possible interaction between PHA nanoparticles (NPs) and pulmonary surfactant using dynamic light scattering, Langmuir balances, and epifluorescence microscopy. Our results demonstrate that NPs deposited onto preformed monolayers of DPPC or DPPC/POPG bind these surfactant lipids. This interaction facilitated the translocation of the nanomaterial towards the aqueous subphase, with the subsequent loss of lipid from the interface. NPs that remained at the interface associated with liquid expanded (LE)/tilted condensed (TC) phase boundaries, decreasing the size of condensed domains and promoting the intermixing of TC and LE phases at submicroscopic scale. This provided the stability necessary for attaining high surface pressures upon compression, countering the destabilization induced by lipid loss. These effects were observed only for high NP loads, suggesting a limit for the use of these NPs in pulmonary drug delivery.

Inhaled formulations and pulmonary drug delivery systems for respiratory infections

2015 ◽  
Vol 85 ◽  
pp. 83-99 ◽  
Author(s):  
Qi (Tony) Zhou ◽  
Sharon Shui Yee Leung ◽  
Patricia Tang ◽  
Thaigarajan Parumasivam ◽  
Zhi Hui Loh ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Respiratory Infections ◽  
Delivery Systems ◽  
Pulmonary Drug Delivery

scholarly journals Micelles Self-Assembled by 3-O-β-D-Glucopyranosyl Latycodigenin Enhance Cell Membrane Permeability, Promote Antibiotic Pulmonary Targeting and Improve Anti-infective Efficacy

2020 ◽  
Author(s):  
Man Zhang ◽  
Lili Ye ◽  
Hao Huang ◽  
Dandan Cheng ◽  
Kaixin Liu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cell Membrane ◽  
Membrane Permeability ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Pulmonary Drug Delivery ◽  
Cell Membrane Permeability ◽  
Bacterial Invasion ◽  
Lung Targeting ◽  
Self Assembled

Abstract Background: Nanoparticle-based pulmonary drug delivery systems are commonly developed and applied for drug-targeted delivery. It exhibits significant advantages compared to traditional pulmonary drug delivery systems. However, developing a formulation for each drug is a time-consuming and laborious task. Results: This study designed and constructed a universal lung-targeting nanoparticle. The self-assembled micelles were composed of a platycodon secondary saponin, 3-O-β-D-glucopyranosyl platycodigenin 682 (GP-682), via its specific amphiphilic structure. GP-682 micelles obtained a relatively stable zeta potential with a particle size between 60 to 90 nm, and the critical micelle concentration (CMC) value was approximately 42.3 μg/mL. Pre-incubation of GP-682 micelles markedly enhanced the cell membrane permeability, and improved drug uptake in vitro. The results were visualized using fluorescent dye tracing, transmission electron microscopy (TEM) observation and lactate dehydrogenase (LDH) releasing assay. The benefits enhanced the distribution of levofloxacin (Lev) in mouse lung tissue and reduced the overdosing of antibiotics. The acute lung injury mice model induced by Pseudomonas aeruginosa PA 14 strain demonstrated that pre-injection of GP-682 micelles before antibiotic administration produced a higher survival rate and anti-infective efficacy in vivo. It included a reduction in pulmonary injury, bacterial invasion and cytokines expression compared to treatment with Lev alone. Conclusions: GP-682 micelles are another nanoparticle-based pulmonary drug delivery system and provides a new option for lung-targeting therapy.

scholarly journals Progress in the Application of Nano- and Micro-based Drug Delivery Systems in Pulmonary Drug Delivery

2021 ◽  
Author(s):  
Rejoice Thubelihle Ndebele ◽  
Qing Yao ◽  
Yan-Nan Shi ◽  
Yuan-Yuan Zhai ◽  
He-Lin Xu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Pharmaceutical Research ◽  
Delivery Systems ◽  
Research Field ◽  
Pulmonary Drug Delivery ◽  
Therapeutic Drug ◽  
Chronic Obstructive ◽  
Wide Range

Nanotechnology is associated with the development of particles in the nano-size range that can be used in a wide range of applications in the medical field. It has gained more importance in the pharmaceutical research field particularly in drug delivery, as it results in enhanced therapeutic drug performance, improved drug solubility, targeted drug delivery to the specific sites, minimized side effects, and prolonged drug retention time in the targeted site. To date, the application of nanotechnology continues to offer several benefits in the treatment of various chronic diseases and results in remarkable improvements in treatment outcomes. The use of nano-based delivery systems such as liposomes, micelles, and nanoparticles in pulmonary drug delivery have shown to be a promising strategy in achieving drug deposition and maintained controlled drug release in the lungs. They have been widely used to minimize the risks of drug toxicity in vivo. In this review, recent advances in the application of nano- and micro-based delivery systems in pulmonary drug delivery for the treatment of various pulmonary diseases, such as lung cancer, asthma, and chronic obstructive pulmonary disease, are highlighted. Limitations in the application of these drug delivery systems and some key strategies in improving their formulation properties to overcome challenges encountered in drug delivery are also discussed.

scholarly journals Pulmonary drug delivery systems for the treatment of tuberculosis

2008 ◽  
Vol 23 (4) ◽  
pp. 474-480
Author(s):  
Hiroyuki Inagawa ◽  
Chie Kohchi ◽  
Gen-ichiro Soma ◽  
Makoto Matsumoto ◽  
Shuji Yamashita ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Pulmonary Drug Delivery
Sign in / Sign up

Export Citation Format

Share Document